华东医药（000963）2025年中报深度解读：创新药业务强势崛起，医美板块承压待转机

<h4 data-pm-slice="0 0 []"><span leaf=""><span textstyle="" style="font-size: 18px;font-weight: bold;">一、业绩概览：净利润超预期增长7%，研发投入激增55%</span></span></h4><p><br /><span leaf="">2025年上半年，华东医药交出了一份"稳中有进"的成绩单：</span></p><ul class="list-paddingleft-1"><li><strong><span leaf="">总营收</span></strong><section><span leaf="">：217亿元（同比增长3.4%）</span></section></li><li><strong><span leaf="">净利润</span></strong><section><span leaf="">：18亿元（同比增长7.0%），超UBS预期7%</span></section></li><li><strong><span leaf="">研发费用</span></strong><section><span leaf="">：10亿元（同比大增55%），研发占比提升至4.6%</span><p><span x-noteelement="excluded" aria-describedby=":r3g:"></span></p></section></li><li><strong><span leaf="">毛利率</span></strong><section><span leaf="">：同比提升1.5个百分点至32.8%</span></section></li></ul><p><br /><em><span leaf="">（创新药业务成为利润增长新引擎）</span></em></p><p><strong><span leaf="">三大业务板块表现</span></strong><span leaf="">：</span></p><ol class="list-paddingleft-1"><li><strong><span leaf="">医药工业</span></strong><section><span leaf="">：收入增长9.2%（创新药收入暴涨59%）</span><p><span x-noteelement="excluded" aria-describedby=":r3i:"></span></p></section></li><li><strong><span leaf="">医药商业</span></strong><section><span leaf="">：收入增长2.8%（增速放缓）</span></section></li><li><strong><span leaf="">医美业务</span></strong><section><span leaf="">：国际/国内市场分别下滑8.0%/12.1%</span><p><span x-noteelement="excluded" aria-describedby=":r3k:"></span></p></section></li></ol><hr style="border-style: solid;border-width: 1px 0 0;border-color: rgba(0,0,0,0.1);-webkit-transform-origin: 0 0;-webkit-transform: scale(1, 0.5);transform-origin: 0 0;transform: scale(1, 0.5);" /><h4><span leaf=""><br /></span></h4><h4><span leaf=""><br /></span></h4><h4><span leaf=""><span textstyle="" style="font-size: 18px;font-weight: bold;">二、创新药业务：收入占比突破15%，多款重磅产品即将放量</span></span></h4><p><br /><strong><span leaf="">核心产品表现</span></strong><span leaf="">：</span></p><ul class="list-paddingleft-1"><li><strong><span leaf="">创新药收入</span></strong><section><span leaf="">：11亿元（同比增长59%），占医药工业收入14.8%</span><p><span x-noteelement="excluded" aria-describedby=":r3m:"></span></p></section></li><li><strong><span leaf="">明星产品</span></strong><section><span leaf="">：乌司奴单抗、Elahere（FRα ADC）、CT053（BCMA CAR-T）快速放量</span><p><span x-noteelement="excluded" aria-describedby=":r3o:"></span></p></section></li><li><strong><span leaf="">在研管线</span></strong><section><span leaf="">：10+项临床数据将在ASH、ADA等国际学术会议公布</span><p><span x-noteelement="excluded" aria-describedby=":r3q:"></span></p></section></li></ul><p><strong><span leaf="">2025下半年催化剂</span></strong><span leaf="">：</span></p><ol class="list-paddingleft-1"><li><strong><span leaf="">新药获批</span></strong><section><span leaf="">：甲磺酸贝福替尼（mefinib）、MB-102有望获NMPA批准</span><p><span x-noteelement="excluded" aria-describedby=":r3s:"></span></p></section></li><li><strong><span leaf="">对外授权</span></strong><section><span leaf="">：GLP-1和多个ADC项目正与跨国药企洽谈合作</span></section></li><li><strong><span leaf="">临床进展</span></strong><section><span leaf="">：HDM2005（ROR1 ADC）Ⅰa期数据、HDM1005（GLP-1/GIP）数据公布</span><p><span x-noteelement="excluded" aria-describedby=":r3u:"></span></p></section></li></ol><p><br /><em><span leaf="">（创新药收入三年复合增长率达42%）</span></em></p><hr style="border-style: solid;border-width: 1px 0 0;border-color: rgba(0,0,0,0.1);-webkit-transform-origin: 0 0;-webkit-transform: scale(1, 0.5);transform-origin: 0 0;transform: scale(1, 0.5);" /><h4><span leaf=""><br /></span></h4><h4><span leaf=""><br /></span></h4><h4><span leaf=""><span textstyle="" style="font-size: 18px;font-weight: bold;">三、医美业务：短期承压但产品管线蓄势待发</span></span></h4><p><br /><strong><span leaf="">市场现状</span></strong><span leaf="">：</span></p><ul class="list-paddingleft-1"><li><strong><span leaf="">国内监管趋严</span></strong><section><span leaf="">：二类械审批周期延长至12-18个月</span></section></li><li><strong><span leaf="">消费降级</span></strong><section><span leaf="">：客单价同比下降15%-20%</span></section></li><li><strong><span leaf="">国际竞争</span></strong><section><span leaf="">：韩国品牌在东南亚市场降价30%抢份额</span></section></li></ul><p><strong><span leaf="">破局策略</span></strong><span leaf="">：</span></p><ol class="list-paddingleft-1"><li><strong><span leaf="">新品储备</span></strong><section><span leaf="">：2026-27年将推出Ellanough M、重组肉毒素、麦莉精密等5款新品</span><p><span x-noteelement="excluded" aria-describedby=":r40:"></span></p></section></li><li><strong><span leaf="">渠道下沉</span></strong><section><span leaf="">：三四线城市专柜覆盖率提升至65%</span></section></li><li><strong><span leaf="">海外调整</span></strong><section><span leaf="">：关闭欧洲3家亏损诊所，聚焦中东高净值客户</span></section></li></ol><p><br /><em><span leaf="">（2026年起每年至少2款新品上市）</span></em></p><hr style="border-style: solid;border-width: 1px 0 0;border-color: rgba(0,0,0,0.1);-webkit-transform-origin: 0 0;-webkit-transform: scale(1, 0.5);transform-origin: 0 0;transform: scale(1, 0.5);" /><h4><span leaf=""><br /></span></h4><h4><span leaf=""><br /></span></h4><h4><span leaf=""><span textstyle="" style="font-size: 18px;font-weight: bold;">四、财务优化：现金流改善，负债结构持续优化</span></span></h4><p><br /><strong><span leaf="">财务健康度提升</span></strong><span leaf="">：</span></p><ul class="list-paddingleft-1"><li><strong><span leaf="">经营现金流</span></strong><section><span leaf="">：同比增长23%至28亿元</span></section></li><li><strong><span leaf="">有息负债率</span></strong><section><span leaf="">：从38%降至32%</span></section></li><li><strong><span leaf="">研发资本化率</span></strong><section><span leaf="">：控制在35%以内（行业平均45%）</span></section></li></ul><p><strong><span leaf="">资本运作亮点</span></strong><span leaf="">：</span></p><ul class="list-paddingleft-1"><li><strong><span leaf="">C-REITs发行</span></strong><section><span leaf="">：盘活存量资产获16亿元现金流入</span></section></li><li><strong><span leaf="">子公司并表</span></strong><section><span leaf="">：控股子公司衡帕贡献利润1.2亿元</span></section></li><li><strong><span leaf="">股息政策</span></strong><section><span leaf="">：维持30%分红比例，对应股息率1.8%</span></section></li></ul><p><br /><em><span leaf="">（净负债/EBITDA从4.2倍降至3.7倍）</span></em></p><hr style="border-style: solid;border-width: 1px 0 0;border-color: rgba(0,0,0,0.1);-webkit-transform-origin: 0 0;-webkit-transform: scale(1, 0.5);transform-origin: 0 0;transform: scale(1, 0.5);" /><h4><span leaf=""><br /></span></h4><h4><span leaf=""><br /></span></h4><h4><span leaf=""><span textstyle="" style="font-size: 18px;font-weight: bold;">五、机构观点：UBS上调目标价至56.6元，维持"买入"评级</span></span></h4><p><br /><strong><span leaf="">UBS最新判断</span></strong><span leaf="">：</span></p><ul class="list-paddingleft-1"><li><strong><span leaf="">目标价</span></strong><section><span leaf="">：56.6元（较现价45.8元有23.6%上行空间）</span></section></li><li><strong><span leaf="">估值逻辑</span></strong><section><span leaf="">：</span></section></li><ul class="list-paddingleft-1"><li><section><span leaf="">医药工业2025年PE 35倍（考虑创新药占比提升）</span></section></li><li><section><span leaf="">医美业务按DCF估值（WACC 6.7%，永续增长率3%）</span><p><span x-noteelement="excluded" aria-describedby=":r42:"></span></p></section></li></ul></ul><p><strong><span leaf="">盈利预测调整</span></strong><span leaf="">：</span></p><table><thead><tr><th><section><span leaf="">指标</span></section></th><th><section><span leaf="">2025E</span></section></th><th><section><span leaf="">2026E</span></section></th><th><section><span leaf="">2027E</span></section></th></tr></thead><tbody><tr><td><section><span leaf="">营收(亿元)</span></section></td><td><section><span leaf="">433.9</span></section></td><td><section><span leaf="">454.4</span></section></td><td><section><span leaf="">476.5</span></section></td></tr><tr><td><section><span leaf="">净利润(亿元)</span></section></td><td><section><span leaf="">37.0</span></section></td><td><section><span leaf="">39.3</span></section></td><td><section><span leaf="">43.7</span></section></td></tr><tr><td><section><span leaf="">EPS(元)</span></section></td><td><section><span leaf="">2.11</span></section></td><td><section><span leaf="">2.24</span></section></td><td><section><span leaf="">2.49</span></section></td></tr></tbody></table><p><br /><em><span leaf="">（近12个月机构目标价持续上调）</span></em></p><hr style="border-style: solid;border-width: 1px 0 0;border-color: rgba(0,0,0,0.1);-webkit-transform-origin: 0 0;-webkit-transform: scale(1, 0.5);transform-origin: 0 0;transform: scale(1, 0.5);" /><h4><span leaf=""><br /></span></h4><h4><span leaf=""><br /></span></h4><h4><span leaf=""><span textstyle="" style="font-size: 18px;font-weight: bold;">六、投资看点：三季报重点关注三大信号</span></span></h4><p><br /><strong><span leaf="">短期观察指标</span></strong><span leaf="">：</span></p><ol class="list-paddingleft-1"><li><strong><span leaf="">创新药放量</span></strong><section><span leaf="">：乌司奴单抗三季度销售能否突破3亿元</span></section></li><li><strong><span leaf="">医美回暖</span></strong><section><span leaf="">：8-9月暑期消费季环比数据改善情况</span></section></li><li><strong><span leaf="">对外授权</span></strong><section><span leaf="">：GLP-1项目海外授权进展</span></section></li></ol><p><strong><span leaf="">长期价值锚点</span></strong><span leaf="">：</span></p><ul class="list-paddingleft-1"><li><section><span leaf="">PARP抑制剂senapib临床数据读出</span></section></li><li><section><span leaf="">甲磺酸贝福替尼进入医保谈判</span></section></li><li><section><span leaf="">重组肉毒素国内Ⅲ期临床完成</span></section></li></ul><p><br /><em><span leaf="">（创新药管线进入密集收获期）</span></em></p><hr style="border-style: solid;border-width: 1px 0 0;border-color: rgba(0,0,0,0.1);-webkit-transform-origin: 0 0;-webkit-transform: scale(1, 0.5);transform-origin: 0 0;transform: scale(1, 0.5);" /><blockquote><p><strong><span leaf="">核心结论</span></strong><span leaf="">：</span><br /><span leaf="">① 创新药收入占比三年内有望突破30%，驱动估值重构</span><br /><span leaf="">② 医美业务2026年新品周期将带来业绩弹性</span><br /><span leaf="">③ 现金流改善为后续BD和研发提供弹药</span></p></blockquote><p><span leaf="">（插入华东医药研发中心实景图）</span><br /><em><span leaf="">数据来源：UBS《Huadong Medicine 2Q25 Review》2025年8月报告</span></em></p><section><span leaf=""><br /></span></section><p style="display: none;"><mp-style-type data-value="3"></mp-style-type></p>